Trial Profile
A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms RA-BEYOND
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 14 Nov 2022 Long-Term Efficacy results presented at the ACR Convergence 2022.
- 04 Jun 2022 Results from RA-BEYOND upto 7 years of treatment presented at the 23rd Annual Congress of the European League Against Rheumatism
- 04 Jun 2022 Results assessing long-term efficacy BARI in bDMARD-IR pts in the completed study RA-BEYOND presented at the 23rd Annual Congress of the European League Against Rheumatism